Aims: Persistent uncertainties exist surrounding the therapeutic drug monitoring (TDM) of adalimumab in clinical settings. To address these issues, we conducted a systematic review to assess the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback